Metlife (MET) AI Stock Analysis

Metlife

(BMV:MET)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Strong Cash GenerationMetLife’s rising operating and free cash flow indicate strong earnings conversion and provide internal funding for dividends, buybacks, capital needs, and growth. This cash-generation capability strengthens financial flexibility and supports shareholder returns across insurance and investment cycles.

Negative Factors

Investment Spread PressureBelow-guidance investment spreads can reduce earnings from retirement and other spread-sensitive products, particularly when private equity and real estate returns are weak. Because investment income is a major insurer earnings driver, persistent spread pressure could constrain profitability and capital-generation momentum.

Metlife (MET) vs. SPDR S&P 500 ETF (SPY)

Market Cap: MXN 63.56B
Dividend Yield: 2.13%
Average Volume (3M): 111
Price to Earnings (P/E): 19.1
Beta (1Y): 0.14
Revenue Growth: -0.80%
EPS Growth: -19.53%
Country: Mexico
Employees: 46,000
Sector: Financial
Sector Strength: 68
Industry: Insurance - Life

Metlife Business Overview & Revenue Model

Company Description

MetLife, Inc. operates as a leading global financial services entity, delivering an extensive array of services encompassing insurance, annuities, employee benefits, and asset management. The company manages its operations through five primary divisi...

Metlife Earnings Call Summary

Earnings Call Date:Aug 04, 2026(Q2-2026)|% Change Since:13.10%|Next Earnings Date:Nov 03, 2026

Earnings Call SentimentPositive

The call conveyed strong, broad-based operational performance and capital returns: adjusted earnings and EPS grew meaningfully, ROE reached the top of the target range, multiple regions delivered double-digit growth (notably Group, Asia and Latin America), AUM grew to $748 billion, and the company announced a new $3 billion buyback while maintaining a healthy holding-company cash buffer. Offsetting risks include below-guidance total spreads driven by weak private equity returns and lower-than-run-rate variable investment income, a lighter and lumpy PRT market in H1, some normalization expected in favorable Group mortality experience, and a short-term earnings impact from mark-to-market items and the PineBridge expense footprint. Overall, positive operational momentum and capital flexibility outweigh the near-term investment and market headwinds.

Positive Updates

Strong Adjusted Earnings and EPS Growth

Adjusted earnings of approximately $1.6 billion ($2.43 per share); adjusted earnings rose 15% year-over-year and adjusted EPS increased 20% year-over-year.

Negative Updates

Normalization Risk in Group Mortality Favorability

Group Life mortality ratio improved to 79% driven in part by about 2 points of prior period development and lower-than-expected severity; management expects some normalization heading into the rest of the year.

Company Guidance

MetLife reiterated its 2026 targets and near‑term expectations, highlighting an annual adjusted ROE target of 15–17% (Q2 at 17%), a 2026 direct expense‑ratio target of 12.1% (Q2 = 12.1% and they expect to beat the full‑year target), MIM adjusted‑earnings guidance of $240–$280M (likely toward the low end) with total AUM of $748B, and RIS spread guidance (core spread ~100 bps; total spread Q2 = 97 bps vs. prior 100–120 bps guidance). Other metrics/guidance included retained‑liability growth of 3–5% (Q2 = +3% Y/Y), holding‑company cash buffer $3–$4B (Q2 cash $3.4B), a new $3B share‑repurchase authorization (Q2 repurchases ≈ $700M; YTD returns >$2.4B and ~$1.1B returned in Q2), estimated U.S. statutory adjusted capital (NAIC) ≈ $16.4B, Japan ESR expected at the top end of a 170–190% range, a Q2 pretax variable investment income run‑rate of $231M (PE avg return 0.8%, real estate/other 1.1% with stronger PE returns expected in Q3), and an effective tax‑rate outlook of ~24–26% (Q2 was 23%).

Metlife Risk Analysis

Metlife disclosed 46 risk factors in its most recent earnings report. Metlife reported the most risks in the "Finance & Corporate" category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

0 New Risks

Metlife Peers Comparison

Overall Rating

UnderperformOutperform

Sector (68)

Financial Indicators

MX:MET against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
UNM	76Outperform	$14.43B	21.24	6.43%	2.12%	3.34%	-48.74%
AFL	72Outperform	$62.11B	13.29	16.42%	1.95%	13.57%	110.75%
PRU	70Outperform	$40.18B	10.44	12.00%	4.77%	9.38%	144.26%
Sector *	68Neutral	$18.00B	11.42	9.92%	3.81%	9.73%	1.22%
LNC	64Neutral	$7.85B	3.42	21.99%	4.39%	12.32%	97.86%
VOYA	58Neutral	$8.88B	16.42	12.63%	1.92%	3.16%	18.32%

* Financial Sector Average

Performance Comparison

MX:MET and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
MX:MET	Metlife	1880.00	467.84	33.13%
AFL	AFLAC Incorporated	123.89	19.11	18.24%
LNC	Lincoln National	41.01	2.23	5.74%
PRU	Prudential Financial	116.45	17.08	17.19%
UNM	Unum Group	91.14	19.89	27.92%
VOYA	Voya Financial	98.05	26.63	37.29%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Metlife AI Stock Analysis